1Ashworth L. Focus on alendronate : A nonhor-monal option for the treatment of osteoporosis in postmenopausal women, Formulary 1996,31(1):23-30.
2Sahni M ,et al:Bisphosphonates act on rat bone resorption through the mediation of osteoblasts,J Clin Invest 1993, 91:2004-2010.
3Azuma Y,et al:Effeets of alendronare on plasma calcium levels,urinary calcium excretion,and hone resorption markers in normal rats: Comparison with elcatonin, synthetic eel calcitonin, Endocrinology 1996,137 (6) : 2586 - 2592.
4Gertz BJ,et al,Stuudies of the oral bioavailability of alendronate,Clin Pharmacol Ther 1995,58 : 288-298.
5Diener KM:Bisphosphonates for controlling pain from metastatic bone disease. Am J HealthSyst pharm 1996,53(16) : 1917-1927.
6Liberman UA,et al: Effect of oral alendronate on boue mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engi J Mcd 1995,333(22):1437-1443.
7Devogelaer JP,et al:Oral alendronate induces progessive increases bone mass of the spine,hip, and total body over 3 years in postmeaopausal women with, osteoporosis. Eone,1996,18(2) :141-150.
8Jeal W,et al:Alendronate A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis.Drugs 1997,3(3):415-434.
9Hayes J, Sambrook P. Alendronate (Fosamax), Clinical utility in metabolic bone disease. Expert ()pin Invest Drugs 1996,5(12):1691-1705.
10Lupoli G, et al, Effects of alendronate on bone loss in pre-and post-menopausal hyperthyroid women treated with methimazole, Gynecol Endocrinol 1996,10(5):343-348.
